454 Sequencing Used at Institute of Genomics and Integrative Biology in India
News May 29, 2008
Roche has installed the first Genome Sequencer FLX System at the IGIB, in Delhi, India. IGIB plans to use the system for all applications possible within this technology, with a special focus on metagenomics and de novo genome sequencing. The Centre for Genomic Application (TCGA) will provide the sequencing services to the customers.
“The launch of the Genome Sequencer FLX System brings in the area of high throughput sequencing in India. We are confident that it will strengthen India’s place at the cutting edge of technology” – said Dr. Bhuwnesh Agrawal, the Managing Director of Indian affiliate of Roche Diagnostics and RAS champion of Asia Pacific.
IGIB, an Institute under CSIR (Council of Scientific & Industrial Research) was created with a mission to translate concepts developed in basic biological research to commercially viable technologies for health care.
Towards this goal IGIB has been actively carrying out research leading to generation of new knowledge and development of technologies in various areas of Biotechnology with a special focus on Genomics and Genome Informatics.
The Centre for Genomic Application (TCGA) is a collaboration between the Institute of Genomics and Integrative Biology (IGIB), supported by Department of Science and Technology (DST) and Institute of Molecular Medicine (IMM-The Chatterjee Group). TCGA is the first ever public private partnership project providing life science services in India.
Genetic Variations in the Lungs Identify COPD RiskNews
Developmental genetic variations in the anatomy of the lung could indicate people at risk of COPD later in life, a study suggests.READ MORE
Proteasome Blocker Brings Glaucoma Gene Therapy CloserNews
An enhanced gene therapy technique that pairs a viral vector with a proteasome blockade has doubled the therapy's efficiency.READ MORE
New Class of Decoy Molecules that Prevent the Onset of PainNews
Researcher report a new method of reducing pain-associated behaviors with RNA-based medicine, creating a new class of decoy molecules that prevent the onset of pain.READ MORE